Vol 17, No 4 (2020)
Review paper
Published online: 2020-09-18
Get Citation

Analysis of neuropsychiatric disorders caused by infection Tropheryma whipplei

Roksana Duszkiewicz, Justyna Gacek, Filip Hajdrowski, Agnieszka Greń, Krzysztof Silski, Miłosz Gołyszny, Tomasz Ludyga
DOI: 10.5603/PSYCH.2020.0037
·
Psychiatria 2020;17(4):224-228.

paid access

Vol 17, No 4 (2020)
Prace poglądowe - nadesłane
Published online: 2020-09-18

Abstract

Whipple’s disease is a rare, chronic systemic infection caused by gram-positive Tropheryma whipplei actinobacterium.
So far, the reasons for the Tropheryma whipplei infection have not been explained. Clinical symptoms are non-specific
and may suggest other diseases, mainly gastrointestinal disease. Nervous system symptoms such as personality disorders,
behavioral disorders, depressive symptoms and disturbances of consciousness are also observed.
The aim of the study is to collect information on neuropsychological disorders found in Whipple’s disease.
Central nervous system (CNS) involvement can take place in three cases: classic form, in the relapse of previously treated
classic form (with changes in the digestive system) and in isolated CNS infection (without evidence of gastrointestinal
involvement by T. whipplei). Neurological disorders resulting from CNS involvement are variable and may be similar to
other diseases of the nervous system. Treatment is difficult due to the long-term course of the disease and non-specificity
of its symptoms, which is why the problem is the selection of effective pharmacotherapy. Untreated disease results
in worsening neuropsychological disorders. Pharmacotherapy involves the use of antibiotics. The use of antibacterial
therapy reduces the risk of recurrence of clinical symptoms.

Abstract

Whipple’s disease is a rare, chronic systemic infection caused by gram-positive Tropheryma whipplei actinobacterium.
So far, the reasons for the Tropheryma whipplei infection have not been explained. Clinical symptoms are non-specific
and may suggest other diseases, mainly gastrointestinal disease. Nervous system symptoms such as personality disorders,
behavioral disorders, depressive symptoms and disturbances of consciousness are also observed.
The aim of the study is to collect information on neuropsychological disorders found in Whipple’s disease.
Central nervous system (CNS) involvement can take place in three cases: classic form, in the relapse of previously treated
classic form (with changes in the digestive system) and in isolated CNS infection (without evidence of gastrointestinal
involvement by T. whipplei). Neurological disorders resulting from CNS involvement are variable and may be similar to
other diseases of the nervous system. Treatment is difficult due to the long-term course of the disease and non-specificity
of its symptoms, which is why the problem is the selection of effective pharmacotherapy. Untreated disease results
in worsening neuropsychological disorders. Pharmacotherapy involves the use of antibiotics. The use of antibacterial
therapy reduces the risk of recurrence of clinical symptoms.

Get Citation

Keywords

Whipple’s disease, Tropheryma whipplei, neuropsychological disorder

About this article
Title

Analysis of neuropsychiatric disorders caused by infection Tropheryma whipplei

Journal

Psychiatria (Psychiatry)

Issue

Vol 17, No 4 (2020)

Article type

Review paper

Pages

224-228

Published online

2020-09-18

DOI

10.5603/PSYCH.2020.0037

Bibliographic record

Psychiatria 2020;17(4):224-228.

Keywords

Whipple’s disease
Tropheryma whipplei
neuropsychological disorder

Authors

Roksana Duszkiewicz
Justyna Gacek
Filip Hajdrowski
Agnieszka Greń
Krzysztof Silski
Miłosz Gołyszny
Tomasz Ludyga

References (38)
  1. La Scola B, Fenollar F, Fournier PE, et al. Description of Tropheryma whipplei gen. nov., sp. nov., the Whipple's disease bacillus. Int J Syst Evol Microbiol. 2001; 51(Pt 4): 1471–1479.
  2. Dobbins W. Whipple's Disease. Mayo Clinic Proceedings. 1988; 63(6): 623–624.
  3. Whipple GHA. hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues. Johns Hopkins Hosp Bull 1907: 383–389.
  4. Yardley J, Hendrix TR. Combined electron and light microscopy in Whipple’s disease: demonstration of “bacillary bones” in the intestine. Johns Hopkins Hosp Bull. 1961; 109: 80–98.
  5. Maizel H, Ruffin JM, Dobbins WO. Whipple’s disease: a review of 19 patients from one hospital and a review of the literature since 1950. Medicine Baltimore 1970: 175–205.
  6. Ratliff NB, McMahon JT, Naab TJ, et al. Whipple's disease in the porcine leaflets of a Carpentier-Edwards prosthetic mitral valve. N Engl J Med. 1984; 311(14): 902–903.
  7. Dobbins WO, Dobbins WO. HLA antigens in Whipple’s disease. Arthritis Rheum. 1987; 30(1): 102–105.
  8. Relman DA, Schmidt TM, MacDermott RP, et al. Identification of the uncultured bacillus of Whipple's disease. N Engl J Med. 1992; 327(5): 293–301.
  9. Wilson KH, Blitchington R, Frothingham R, et al. Phylogeny of the Whipple's-disease-associated bacterium. Lancet. 1991; 338(8765): 474–475.
  10. Maiwald M, Ditton HJ, von Herbay A, et al. Reassessment of the phylogenetic position of the bacterium associated with Whipple's disease and determination of the 16S-23S ribosomal intergenic spacer sequence. Int J Syst Bacteriol. 1996; 46(4): 1078–1082.
  11. Stackebrandt E, Liesack W, Goebel BM. Bacterial diversity in a soil sample from a subtropical Australian environment as determined by 16S rDNA analysis. FASEB J. 1993; 7(1): 232–236.
  12. Kiyoaki U, Takashi S, Tomonori Y, et al. Central nervous system relapse of Whipple’s disease. Intern Med. 2012; 51(15): 2045–2050.
  13. Schoedon G, Goldenberger D, Forrer R, et al. Deactivation of macrophageswith interleukin-4 is the key to the isolation of Tropheryma whippeli. J Infect Dis . 1997; 176(5): 672–677.
  14. Marth T, Neurath M, Cuccherini BA, et al. Defects of monocyte interleukin 12 production and humoral immunity in Whipple's disease. Gastroenterology. 1997; 113(2): 442–448.
  15. Schneider T, Stallmach A, von Herbay A, et al. Treatment of refractory Whipple disease with interferon-gamma. Ann Intern Med. 1998; 129(11): 875–877.
  16. Papaliodis GN. Whipple’s Disease. In: Papaliodis GN. ed. Uveitis: A Practical Guide to the Diagnosis and Treatment of Intraocular Inflammation. Springer 2017: 117–118.
  17. Kniehl MM. Whipple – epidemiologie und aetiologie. Der Mikrobiol. 1994; 4: 123–126.
  18. Hendrix JP, Black-Schaffer B, Withers P, et al. Whipple's intestinal lipodystrophy; report of four cases and discussion of possible pathogenic factors. Arch Intern Med. 1950; 85(1): 91–131.
  19. Fenollar F, Raoult D. Molecular techniques in Whipple’s disease. Expert Rev Mol Diagn. 2001; 1(3): 299–309.
  20. Maiwald M, Schuhmacher F, Ditton HJ, et al. Environmental occurrence of the Whipple's disease bacterium (Tropheryma whippelii). Appl Environ Microbiol. 1998; 64(2): 760–762.
  21. Braubach P, Lippmann T, Raoult D, et al. Fluorescence hybridization for diagnosis of Whipple's disease in formalin-fixed paraffin-embedded tissue. Front Med (Lausanne). 2017; 4: 87.
  22. Dymon I, Tabaka-Pradela J, Knast K, et al. Objawy neurologiczne i neuropsychologiczne w przewlekłej postaci choroby Whipple’a–opis przypadku. Psychiatr Pol. 2017; 51(5): 953–961.
  23. Louis ED, Lynch T, Kaufmann P, et al. Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol. 1996; 40(4): 561–568.
  24. Durand D, Lecomte C, Cathébras P, et al. Whipple Disease: Clinical Review of 52 Cases. Medicine. 1997; 76(3): 170–184.
  25. Dobbins WO. The diagnosis of Whipple's disease. N Engl J Med. 1995; 332(6): 390–392.
  26. Berthelot JM, Puéchal X, Gaudé M, et al. Whipple's disease. Joint Bone Spine. 2002; 69(2): 133–140.
  27. Sieracki JC. Whipple's disease-observation on systemic involvement. I. Cytologic observations. AMA Arch Pathol. 1958; 66(4): 464–467.
  28. Lagier JC, Lepidi H, Raoult D, et al. Systemic Tropheryma whipplei: clinical presentation of 142 patients with infections diagnosed or confirmed in a reference center. Medicine (Baltimore). 2010; 89(5): 337–345.
  29. Gerard A, Sarrot-Reynauld F, Liozon E, et al. Neurologic presentation of Whipple disease: report of 12 cases and review of the literature. Medicine (Baltimore). 2002; 81(6): 443–457.
  30. Dobbins W. Whipple's Disease. Mayo Clinic Proceedings. 1988; 63(6): 623–624.
  31. Compain C, Sacre K, Puéchal X, et al. Central nervous system involvement in Whipple disease: clinical study of 18 patients and long-term follow-up. Medicine (Baltimore). 2013; 92(6): 324–330.
  32. Manzel K, Tranel D, Cooper G. Cognitive and behavioral abnormalities in a case of central nervous system Whipple disease. Arch Neurol. 2000; 57(3): 399–403.
  33. França MC, Castro Rde, Balthazar ML, et al. Whipple's disease with neurological manifestations: case report. Arq Neuropsiquiatr. 2004; 62(2A): 342–346.
  34. Matthews BR, Jones LK, Saad DA, et al. Cerebellar ataxia and central nervous system whipple disease. Arch Neurol. 2005; 62(4): 618–620.
  35. Feurle GE, Marth T. An evaluation of antimicrobial treatment for Whipple's Disease. Tetracycline versus trimethoprim-sulfamethoxazole. Dig Dis Sci. 1994; 39(8): 1642–1648.
  36. Misbah SA, Mapstone NP. Whipple's disease revisited. J Clin Pathol. 2000; 53(10): 750–755.
  37. Schnider PJ, Reisinger EC, Berger T, et al. Treatment guidelines in central nervous system Whipple's disease. Ann Neurol. 1997; 41(4): 561–562.
  38. Wroe SJ, Pires M, Harding B, et al. Whipple's disease confined to the CNS presenting with multiple intracerebral mass lesions. J Neurol Neurosurg Psychiatry. 1991; 54(11): 989–992.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl